Celgene Corp., the maker of cancer-fighting drugs Istodax and Abraxane, sold $1.5 billion of bonds in its first offering in about two years.
The biopharmaceutical company issued $500 million of 1.9 percent, five-year notes to yield 130 basis points more than similar-maturity Treasuries and $1 billion of 3.25 percent, 10-year debt at a relative yield of 170 basis points, according to data compiled by Bloomberg.
Celgene last sold debt in a three-part offering in October 2010, issuing $500 million each of 2.45 percent, five-year debt and 3.95 percent, 10-year bonds and $250 million of 5.7 percent 30-year securities, Bloomberg data show.
The new bonds may be rated Baa2, the second-lowest level of investment grade, by Moody’s Investors Service, according to a person familiar with the transaction, who asked not to be identified because the terms are private.
Bank of America Corp., JPMorgan Chase & Co. and Morgan Stanley managed the sale for the Summit, New Jersey-based company, Bloomberg data show. Proceeds will be used for general corporate purposes.